Novavax Inc (NVAX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.33B
Last updated: Nov 17, 2026 at 4:41 PM ET
Novavax Inc (NVAX) Statistics
Novavax (NVAX) has a market cap of $1.33B and an enterprise value of $1.40B. Revenue fell 61.33% over the last 12 months from the 12 months before. It kept -18.64% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 5.24% above the market cap, as debt exceeds cash.
| Market Cap | $1.33B |
|---|---|
| Enterprise Value | $1.40B |
| Latest price (Nov 17, 2026) | $7.96 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 3.2x. Its year-end P/S ranged from 0.4x to 455.3x from 2016 to 2025.
| P/S Ratio | 3.2x |
|---|---|
| Forward P/S | 2.8x |
Price Statistics
The stock is up 14.20% over 52 weeks and trades 23.83% below its 50-day average.
| Beta (1Y) | 2.10 |
|---|---|
| 52-Week Change | +14.20% |
| 1-Month Change | -26.43% |
| 3-Month Change | -9.44% |
| 6-Month Change | -10.56% |
| 5-Year Change | -93.23% |
| 10-Year Change | -66.84% |
| Total Return (1Y) | +14.20% |
| Total Return (3Y CAGR) | +11.58% |
| Total Return (5Y CAGR) | -47.06% |
| Return vs SPY (1Y) | +9.60% |
| Max Drawdown (1Y) | -37.91% |
| Max Drawdown (3Y) | -74.11% |
| Sharpe Ratio (1Y) | 0.27 |
| Correlation with SPY (1Y) | 0.40 |
| 50-Day Average | $10.45 |
| 200-Day Average | $9.33 |
| 52-Week Range | $6.20 to $13.39 |
| RSI (14 Days) | 34.7 |
| Average Volume (20 Days) | 6.01M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.15x current liabilities.
| Current Ratio | 2.15x |
|---|---|
| Quick Ratio | 2.09x |
| Interest Coverage | 9.63x |
Returns and Efficiency
Return on invested capital is -66.62% over the last 12 months.
| Return on Assets (ROA) | -8.64% |
|---|---|
| Return on Invested Capital (ROIC) | -66.62% |
| Return on Capital Employed (ROCE) | -8.98% |
| ROA (5Y Average) | -20.34% |
| Asset Turnover | 0.40x |
| Inventory Turnover | 6.35x |
| Receivables Turnover | 12.13x |
| Cash Conversion Cycle | -9 days |
Scores
NVAX has an Altman Z-Score of -5.85, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -5.85 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $411.65M over the last 12 months.
| Revenue | $411.65M |
|---|---|
| Revenue Growth (YoY) | -61.33% |
| Gross Profit | $321.12M |
| Operating Income | -$87.39M |
| Pretax Income | -$71.93M |
| Net Income | -$76.73M |
| EBITDA | -$35.83M |
| EBIT | -$50.12M |
| Reported EPS (TTM) | -$0.46 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $222.46M |
|---|---|
| Total Debt | $292.09M |
| Net Debt | $69.63M |
| Net Debt Per Share | $0.42 |
| Working Capital | $378.11M |
| Shareholder Equity | -$216.85M |
| Tangible Book Value | -$328.93M |
| Total Assets | $888.00M |
| Total Liabilities | $1.10B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $5.13M of capital spending, operating cash flow left -$244.07M of free cash flow.
| Operating Cash Flow | -$238.95M |
|---|---|
| Capital Expenditures | $5.13M |
| Free Cash Flow | -$244.07M |
| FCF Per Share | -$1.48 |
| Depreciation and Amortization | $14.29M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -21.23%, against a 5-year average of -46.69%.
| Gross Margin | 78.01% |
|---|---|
| Operating Margin | -21.23% |
| Pretax Margin | -17.47% |
| Net Margin | -18.64% |
| EBITDA Margin | -8.70% |
| EBIT Margin | -12.17% |
| FCF Margin | -59.29% |
| Gross Margin (5Y Average) | 76.66% |
| Operating Margin (5Y Average) | -46.69% |
| Net Margin (5Y Average) | -45.80% |
Growth
Revenue fell 17.24% a year over 3 years.
| Revenue Growth (3Y CAGR) | -17.24% |
|---|---|
| Revenue Growth (5Y CAGR) | +18.76% |
Dividends and Yields
NVAX does not pay a dividend. Its free cash flow yield is -18.59%.
| FCF Yield | -18.59% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-20 reverse split on May 10, 2019.
| Last Split Date | May 10, 2019 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Peer Position
Against 10 similar companies, NVAX has the 7th highest P/S.
P/S RatioPeer median 5.1x
ROICPeer median -28.26%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +12.82%
| P/S Ratio | 3.2x vs 5.1x median |
|---|---|
| ROIC | -66.62% vs -28.26% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -61.33% vs +12.82% median |
Analyst Forecast
Consensus estimates put revenue growth at -53.20% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -53.20% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About NVAX
What is NVAX's market cap?
Novavax has a market cap of $1.33B. Its enterprise value, which adds debt and subtracts cash, is $1.40B.
How many shares of NVAX are outstanding?
Novavax has 164.92M shares outstanding. The count is up 1.58% from a year earlier.
Does NVAX pay a dividend?
No. Novavax does not pay a dividend.
How much debt does NVAX have?
Novavax has $292.09M of total debt and $222.46M of cash and equivalents, a net debt position of $69.63M.
NVAX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors